Tokyo:Lymphocyte regeneration potential of iPS cells as cancer therapy in the future.
Previous studies have shown that T killer lymphocytes are produced in the laboratory using the conventional method is not efficient in killing cancer cells. Trutama because very short period of his life, which limits its use as a treatment for cancer.
To solve the problem, Japanese researchers led by Hiroshi Kawamoto mereprogram killer T lymphocytes in the adult human iPS cells and investigated the differences in these cells.
Tim induces T lymphocytes that are specific to certain types of skin cancer to reprogram into iPS cells by exposing lymphocytes to the Yamanaka factors, a group of compounds that induce the cells to return to the stage that is not special.
IPS cells were obtained and grown in the laboratory and induced to differentiate into T lymphocytes killer again.
"We have managed to expand antigen-specific T cells to make iPS cells and differentiate them back into functional T cells".
"The next step is to test whether T cells can selectively kill tumor cells, but the cells no other cells in the body. If they do, these cells may be directly injected into the patient to therapy. This can be realized in a not so far away. "
The findings were published in the journal of Cell Stem Cell.
The researchers said the killer T cells specific cancers were injected directly into the cancer patients for therapy. And by injecting large amounts of it can boost the immune system. You see, the cells naturally occurring in the body in small numbers.
Researchers at the RIKEN Research Center for Allergy and Immunology reveals his success in creating the cells of the immune system called T lymphocytes killer as quoted Dailymail, Friday (04/01/2013).
In him, the first time the team had to do reprogram T lymphocytes that specifically kill certain types of cancer, all other cell types called cells induced pluripotent stem cells (iPS).
